Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma

被引:65
|
作者
Sahlmann, Carsten-Oliver [1 ]
Meller, Birgit [1 ]
Bouter, Caroline [1 ]
Ritter, Christian Oliver [2 ]
Stroebel, Philipp [4 ]
Lotz, Joachim [2 ]
Trojan, Lutz [3 ]
Meller, Johannes [1 ]
Hijazi, Sameh [3 ]
机构
[1] Univ Med Ctr Goettingen, Dept Nucl Med, Robert Koch Str 40, D-37075 Gottingen, Germany
[2] Univ Med Ctr Goettingen, Dept Diagnost & Intervent Radiol, D-37075 Gottingen, Germany
[3] Univ Med Ctr Goettingen, Dept Urol, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen, Dept Pathol, D-37075 Gottingen, Germany
关键词
Prostate carcinoma; PSMA; HBED; PET; PET/CT; 68Ga; DUAL-TIME-POINT; GA-68-LABELED PSMA LIGAND; BIOCHEMICAL RECURRENCE; PET; DIAGNOSIS; IMPACT;
D O I
10.1007/s00259-015-3251-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Binding of Ga-68-PSMA-HBED-CC (Ga-68-PSMA) at prostate cancer (PC) cells increases over time. A biphasic protocol may help separating benign from tumor lesions. The aim of this study was the retrospective evaluation of a diagnostic incremental value of a dual-time point (biphasic) Ga-68-PSMA-PET/CT in patients with prostate cancer. Methods Retrospective analysis of 35 consecutive patients (49-78 years, median 71) with newly diagnosed PC (12/35) or recurrence of PC (23/35). PET/CT (Gemini TF16, Philips) was acquired 1 h and 3 h p. i. of 140-392 MBq (300 MBq median) Ga-68-PSMA, followed by a diagnostic contrast CT. PET findings were correlated with histology or unequivocal CT findings. Semiquantitative PET data (SUVmax, SUV mean) were acquired and target-to-background-ratios (T/B-ratio) were calculated for benign and malign lesions for both time points. Size of lymph nodes (LN) on diagnostic CT was recorded. Statistical analysis was performed for assessment of significant changes of semiquantitative PET-parameters over time and for correlation of size and uptake of lymph nodes. Results One hundred and four lesions were evaluated. Sixty lesions were referenced by histology or unequivocal CT findings, including eight (13.3 %) histopathologically benign lymph nodes, 12 (20 %) histopathologically lymph node metastases, 12 (20 %) primary tumors, three (5 %) local recurrences, and 25 (41.7 %) bone metastases. Forty-four lesions were axillary LN with normal CT-appearance. Benign lesions had significantly lower SUVmax and T/B-ratios compared with malignant findings. Malign lesions showed a significant increase of both parameters over time compared to benign findings. There was no correlation between LN size and SUVmax. The sensitivity, specificity, the positive predictive value and negative predictive value of PET/CT regarding pelvic LN was 94 %, 99 %, 89 %, and 99.5 %, respectively. Conclusions In contrast to benign tissues, the uptake of proven tumor lesions increases on Ga-68-PSMA-PET/CT over time. A biphasic PET-study may lead to a better detection of tumor lesions in unequivocal findings.
引用
收藏
页码:898 / 905
页数:8
相关论文
共 50 条
  • [1] Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma
    Carsten-Oliver Sahlmann
    Birgit Meller
    Caroline Bouter
    Christian Oliver Ritter
    Philipp Ströbel
    Joachim Lotz
    Lutz Trojan
    Johannes Meller
    Sameh Hijazi
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 898 - 905
  • [2] Use of 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) PET/CT At Initial Staging For Intermediate And High-Risk Prostate Cancer
    dos Santos, G.
    Banchero, A.
    Leiva, J.
    Trindade, V.
    Savio, E.
    Vilche, S.
    Perez, L.
    Gambini, J.
    Duarte, P.
    Alonso, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S538 - S538
  • [3] 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer
    Elif Neslihan Akdemir
    Murat Tuncel
    Fadıl Akyol
    Cenk Yucel Bilen
    Dilek Ertoy Baydar
    Erdem Karabulut
    Haluk Ozen
    Meltem Caglar
    World Journal of Urology, 2019, 37 : 813 - 821
  • [4] 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer
    Akdemir, Elif Neslihan
    Tuncel, Murat
    Akyol, Fadil
    Bilen, Cenk Yucel
    Baydar, Dilek Ertoy
    Karabulut, Erdem
    Ozen, Haluk
    Caglar, Meltem
    WORLD JOURNAL OF UROLOGY, 2019, 37 (05) : 813 - 821
  • [5] Two-phase 68Ga-PSMA-HBED-PET/CT in patients with high-risk prostate carcinoma or PSA-relapse
    Bouter, C.
    Meller, B.
    Ritter, C. O.
    Lotz, J.
    Meller, J.
    Hijazi, S.
    Sahlmann, C. O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S124 - S124
  • [6] Role of 68Ga-PSMA-HBED-CC PET/CT in Patients with Anaplastic Thyroid Carcinoma
    Subudhi, T. Kishan
    Damle, Nishikant
    Arora, Geetanjali
    Bal, Chandrasekhar
    Tripathi, Madhavi
    Kumar, Chitresh
    Agarwal, Shipra
    Kumar, Ritesh
    Kumar, Rajeev
    Ranjan, Piyush
    Madan, Karan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [7] Integrated 68Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer
    Luetje, Susanne
    Cohnen, Joseph
    Gomez, Benedikt
    Grueneisen, Johannes
    Sawicki, Lino M.
    Ruebben, Herbert
    Bockisch, Andreas
    Umutlu, Lale
    Poeppel, Thorsten D.
    Wetter, Axel
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2017, 56 (03): : 73 - 81
  • [8] 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
    Sathekge, Mike
    Lengana, Thabo
    Modiselle, Moshe
    Vorster, Mariza
    Zeevaart, JanRijn
    Maes, Alex
    Ebenhan, Thomas
    Van de Wiele, Christophe
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) : 689 - 694
  • [9] 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
    Mike Sathekge
    Thabo Lengana
    Moshe Modiselle
    Mariza Vorster
    JanRijn Zeevaart
    Alex Maes
    Thomas Ebenhan
    Christophe Van de Wiele
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 689 - 694
  • [10] Role of early dynamic PET/CT with 68Ga-PSMA-HBED-CC in patients with adenocarcinoma prostate
    Perveen, Gazala
    Arora, Geetanjali
    Damle, Nishikant
    Gupta, Ravikant
    Tripathi, Madhavi
    Bal, Chandrasekhar
    Kumar, Praveen
    Rajeev, Kumar
    Prabhu, Meghana
    Singh, Prabhjot
    Das, Chandan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59